Timing of Anti-Drug Antibody Testing After TNF Inhibitor Discontinuation
The type of laboratory assay used determines when you can reliably draw anti-drug antibodies after stopping a TNF inhibitor, but drug-sensitive assays require waiting until circulating drug is cleared (approximately 4 half-lives), while drug-tolerant assays can detect antibodies in the presence of drug and do not require a waiting period. 1
Understanding Assay Types and Their Implications
The critical factor in timing antibody testing is the laboratory methodology employed:
Drug-Sensitive vs. Drug-Tolerant Assays
Drug-sensitive assays have limited ability to detect anti-drug antibodies when circulating drug is present due to formation of antibody-drug complexes that mask detection 1
Drug-tolerant assays can detect anti-drug antibodies even in the presence of detectable drug, eliminating the need to wait for drug clearance 1
The interpretation of immunogenicity data must be done in the context of which laboratory method was used 1
Recommended Waiting Periods (If Using Drug-Sensitive Assays)
If your laboratory uses drug-sensitive assays, wait approximately 4 half-lives before drawing antibody levels to ensure adequate drug clearance:
- Etanercept: Wait 2 weeks (half-life ~3-5 days) 1
- Adalimumab: Wait 6-8 weeks (half-life ~10-20 days) 1
- Infliximab: Wait 4-6 weeks (half-life ~7-12 days) 1
These timeframes are extrapolated from perioperative discontinuation guidelines and represent the time needed for drug clearance 1
Clinical Context for Antibody Testing
When Antibody Testing Is Appropriate
Testing for anti-drug antibodies is rated appropriate in several scenarios:
- At the end of induction therapy in primary non-responders 2
- In secondary non-responders (loss of response during maintenance) 2
- At least once during the first year of maintenance therapy 2
- Following a drug holiday (treatment interruption) 2
Important Caveats About Antibody Interpretation
Antibodies can be transient: Anti-drug antibodies have been shown to return to normal in a minority of patients when repeated 4 weeks later 1
Positivity thresholds matter: Detection depends on the assay type, dilution accuracy, and positivity thresholds used by the laboratory 1
Low-level antibodies have clinical significance: For adalimumab, even low-concentration anti-drug antibodies (6-10 AU/mL using validated thresholds) are associated with lower drug levels and treatment failure 3
Practical Algorithm for Testing
If drug-tolerant assay is available:
- Draw antibodies at any time, regardless of when TNF inhibitor was stopped 1
If only drug-sensitive assay is available:
- Wait 4-6 weeks after stopping infliximab 1
- Wait 6-8 weeks after stopping adalimumab 1
- Wait 2 weeks after stopping etanercept 1
After obtaining results: